Thus, by uncovering loci that predispose to CH, it may be possible to identify potential therapeutic targets (e.g., TCL1A) and develop strategies to intervene in the early stages of diseases that are promoted by CH. This evidence concerns the gene TCL1A and cyclic hematopoiesis.